title: [Sclerosing encapsulating peritonitis: current features].
abstract: We report three original cases of sclerosing encapsulating peritonitis (SEP) which is a rare but severe complication of peritoneal dialysis (PD). In the report of case 1, SEP occurred in a 75-year-old diabetic patient mellitus 18 years after the arrest of PD technique recurrent infectious peritonitis. The switch to hemodialysis was associated with a chronic inflammatory state poorly explained until the discovery of SEP. For case 2, SEP started within seven months after automated PD initiation in a severe septic context leading to leg amputation in a 57-year-old unstable diabetic male. In the last case, 84-year-old woman presented SEP after several peritonitis episodes, including one due to acute pancreatitis. In all cases, SEP was confirmed by open surgery. All patients were treated by visceralysis. The outcome was favorable in two of these three patients. SEP mechanisms, risks factors, prognosis and treatment are discussed with reference to the literature.
authors.affiliation: Service de nephrologie, groupe hospitalo-universitaire Caremeau, place du Professeur-Robert-Debré, 30029 Nîmes cedex 09, France.
authors.forename: Mounia
authors.initials: M
authors.lastname: Tagnaouti
authors.forename: Bernard
authors.initials: B
authors.lastname: Branger
authors.forename: Céline
authors.initials: C
authors.lastname: Ied
authors.forename: Pascal
authors.initials: P
authors.lastname: Reboul
authors.forename: Bachir
authors.initials: B
authors.lastname: Zabadani
authors.forename: Frédérique
authors.initials: F
authors.lastname: Vecina
authors.forename: Gérard
authors.initials: G
authors.lastname: Deschodt
authors.forename: Jean
authors.initials: J
authors.lastname: Carolfi
authors.forename: Michel
authors.initials: M
authors.lastname: Prudhomme
authors.forename: Guilhem
authors.initials: G
authors.lastname: Godlevski
mesh_terms: D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D017809:Fatal Outcome; D006801:Humans; D007422:Intestines / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D010195:Pancreatitis / Q000150:complications; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000175:diagnosis / Q000209:etiology* / Q000382:microbiology / Q000473:pathology / Q000628:therapy; D011183:Postoperative Complications; D012008:Recurrence; D012307:Risk Factors; D012598:Sclerosis / Q000209:etiology / Q000473:pathology
chemical_list: D000319:Adrenergic beta-Antagonists